Agent for treatment of exocrine gland disorders and transgenic mouse useful for screening the same
AssigneeR-Tech Ueno, Ltd.
InventorsKazuo Tsubota, Ichiro Saito
Life of this patent
Estimating the term…
Abstract
An agent for treating exocrine gland disorders by inhibiting the production and/or an activity of interleukin-10; and a transgenic mouse useful for screening the same wherein interleukin-10 is specifically expressed in its exocrine glands.
Claims10
Agent for treatment of exocrine gland disorders, comprising a substance which inhibits the production and/or an activity of interleukin-10 as an active ingredient.
A method for screening an agent for treatment of exocrine gland disorders, comprising the step of detecting cytotoxic ability of Fas-ligand expressed by interleukin-10.
A method for screening an agent for treatment of exocrine gland disorders, comprising the steps of:
- adding effector cells, which are obtainable by treating said cells with interleukin-10, to aliquots of exocrine gland target cells;
- adding to the resulting cell mixtures either interleukin-10 alone or a mixture of interleukin-10 and a substrate to be screened;
- incubating the cell mixtures;
- and
- calculating the cytotoxic ratio from the amount of damaged target cells occurs in the respective cell mixtures.
A plasmid comprising the following restriction map:
- 3
- which is obtainable by ligating 640 bp of splicing region of rabbit beta globulin to 828 bp of human amylase promoter and 594 bp of IL-10 cDNA to the 3′-terminal of the splicing region.
A method for preparing a plasmid vector comprising the steps of:
- ligating rabbit beta globulin splicing region to BamH1 digested fragment of human exocrine gland promoter,
- ligating EcoR1 digested fragment of mouse interleukin-10 cDNA to the 3′ end of the splicing region;
- and
- inserting the resulting plasmid into a selective marker.
Dependencies are inferred from the claim text.